Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Advanced Cancer × Erlotinib Hydrochloride × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 122 Lung Neoplasms 46 Pancreatic Neoplasms 29 Non-Squamous Non-Small Cell Lung Cancer 15 Neoplasms 15 Glioblastoma 12 Gliosarcoma 11 Breast Neoplasms 11 Adenocarcinoma of Lung 11 Brain Neoplasms 10 Neoplasm Metastasis 9 Head and Neck Neoplasms 9 Carcinoma, Renal Cell 7 Carcinoma, Hepatocellular 7 Carcinoma, Squamous Cell 6 Astrocytoma 6 Adenocarcinoma, Bronchiolo-Alveolar 6 Squamous Cell Carcinoma of Head and Neck 5 Oligodendroglioma 5 Urinary Bladder Neoplasms 4 Glioma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma 4 Adenocarcinoma 4 Recurrence 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Liver Neoplasms 3 Kidney Neoplasms 3

Interventions

Nivolumab 7 linrodostat 3 Ipilimumab 3 relatlimab 2 Pemetrexed 2 tislelizumab 1 regorafenib 1 ralimetinib 1 p38 Mitogen-Activated Protein Kinases 1 figitumumab 1 efatutazone 1 abemaciclib 1 Vorinostat 1 Tamoxifen 1 Sunitinib 1 Ranitidine 1 Midazolam 1 LY2603618 1 LY2584702 1 Gemcitabine 1 Fulvestrant 1 Dasatinib 1 Crizotinib 1 Cetuximab 1 Carboplatin 1 BMS-813160 1 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡